Who are Pegylated-Proline-interferon alpha-2b's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PegIFN alfa-2a, Peg-P-IFN-alpha-2b (AOP2014).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pegylated-proline-interferon-alpha-2b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pegylated-Proline-interferon alpha-2b — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pegylated-Proline-interferon alpha-2b (Pegylated-Proline-interferon alpha-2b) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pegylated interferon alpha. Area: Virology/Hepatology.

phase 3 Pegylated interferon alpha Interferon-alpha receptor (IFNAR) Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Pegylated-Proline-interferon alpha-2b (Pegylated-Proline-interferon alpha-2b) — AOP Orphan Pharmaceuticals AG. Pegylated-Proline-interferon alpha-2b is a modified interferon alpha-2b with extended half-life that activates innate immune responses through interferon-alpha receptor signaling.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pegylated-Proline-interferon alpha-2b TARGET	Pegylated-Proline-interferon alpha-2b	AOP Orphan Pharmaceuticals AG	phase 3	Pegylated interferon alpha	Interferon-alpha receptor (IFNAR)
PegIFN alfa-2a	PegIFN alfa-2a	The Second Affiliated Hospital of Chongqing Medical University	marketed	Pegylated interferon alpha	Interferon-alpha receptor (IFNAR)
Peg-P-IFN-alpha-2b (AOP2014)	Peg-P-IFN-alpha-2b (AOP2014)	AOP Orphan Pharmaceuticals AG	phase 3	Pegylated interferon alpha	Interferon alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pegylated interferon alpha class)

AOP Orphan Pharmaceuticals AG · 2 drugs in this class
The Second Affiliated Hospital of Chongqing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pegylated-Proline-interferon alpha-2b — Competitive Intelligence Brief. https://druglandscape.com/ci/pegylated-proline-interferon-alpha-2b. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing